3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
7
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Pain
2
Motor Activity
2
Hematopoietic and Lymphatic System Neoplasm
2
Carcinoma, Non-Small-Cell Lung
2
Breast Carcinoma In Situ
2
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Sedentary Behavior
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Pulmonary Disease, Chronic Obstructive
1
Polyps
1
Patient Satisfaction
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Neuromuscular Junction Diseases
1
Nervous System Diseases
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Myasthenia Gravis
1
Muscle Weakness
1
Metastatic Pancreatic Adenocarcinoma
1
Malignant Hepatobiliary Neoplasm
1
Interventions
Cyclophosphamide
8
fludarabine phosphate
6
fludarabine
5
Bendamustine Hydrochloride
4
Busulfan
3
AP 1903 reagent
3
pembrolizumab
2
Tacrolimus
2
Mycophenolic Acid
2
thymoglobulin
1
pimonidazole
1
palbociclib
1
ibritumomab tiuxetan
1
Valsartan
1
Telemedicine
1
Surveys and Questionnaires
1
Rivaroxaban
1
Rituximab
1
Radiotherapy
1
Plasmalyte A
1
Pharmacogenomic Testing
1
Melphalan
1
Hydroxychloroquine
1
Etoposide
1
Dimethyl Sulfoxide
1
Cytarabine
1
Carmustine
1
Bone Marrow Transplantation
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Immune System Diseases
×
Telemedicine
×
Clear all
NCT05917184
2023-06-23
ADAPT-teleMG
Yale University
Completed
52 enrolled